Comparative Pharmacology
Head-to-head clinical analysis: ROBAXIN versus STRIFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROBAXIN versus STRIFON FORTE DSC.
ROBAXIN vs STRIFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.
Caffeine is a central nervous system stimulant that acts as an antagonist at adenosine receptors (A1 and A2A subtypes), thereby reducing the inhibitory effects of adenosine. Dihydroergotamine is an ergot alkaloid with partial agonist activity at serotonin 5-HT1B/1D receptors, leading to vasoconstriction of cranial blood vessels. Thioridazine is a typical antipsychotic with high affinity for dopamine D2 receptors and moderate affinity for serotonin 5-HT2A, alpha1-adrenergic, and histamine H1 receptors.
1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 mL) as a single intravenous injection or infusion.
Chlorzoxazone 500 mg to 750 mg orally three to four times daily.
None Documented
None Documented
1-2 hours in adults; clinically, multiple daily dosing required to maintain effect.
10-12 hours in healthy adults; prolonged to 18-24 hours in hepatic impairment or elderly
Renal excretion of metabolites accounts for 99% of elimination; <1% excreted as unchanged drug in urine.
Renal excretion of unchanged drug (70-90%) and glucuronide conjugates; biliary/fecal elimination accounts for <10%
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant